Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma

2021
journal article
article
32
cris.lastimport.wos2024-04-10T01:56:21Z
dc.affiliationWydział Lekarski : Klinika Hematologiipl
dc.cm.date2022-04-08T06:14:05Z
dc.cm.id103343pl
dc.cm.idOmegaUJCM238a6771135143538b735471d2301748pl
dc.contributor.authorSalles, Gillespl
dc.contributor.authorDługosz-Danecka, Monika - 357459 pl
dc.contributor.authorGhesquieres, Hervépl
dc.contributor.authorJurczak, Wojciech - 129923 pl
dc.date.accession2022-02-01pl
dc.date.accessioned2022-04-08T06:14:05Z
dc.date.available2022-04-08T06:14:05Z
dc.date.issued2021pl
dc.description.number4pl
dc.description.physical455-463pl
dc.description.volume21pl
dc.identifier.doi10.1080/14712598.2021.1884677pl
dc.identifier.eissn1744-7682pl
dc.identifier.issn1471-2598pl
dc.identifier.urihttps://ruj.uj.edu.pl/xmlui/handle/item/290042
dc.languageengpl
dc.language.containerengpl
dc.rightsDodaję tylko opis bibliograficzny*
dc.rights.licenceBez licencji otwartego dostępu
dc.rights.uri*
dc.subtypeArticlepl
dc.titleTafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphomapl
dc.title.journalExpert Opinion on Biological Therapypl
dc.typeJournalArticlepl
dspace.entity.typePublication
cris.lastimport.wos
2024-04-10T01:56:21Z
dc.affiliationpl
Wydział Lekarski : Klinika Hematologii
dc.cm.date
2022-04-08T06:14:05Z
dc.cm.idpl
103343
dc.cm.idOmegapl
UJCM238a6771135143538b735471d2301748
dc.contributor.authorpl
Salles, Gilles
dc.contributor.authorpl
Długosz-Danecka, Monika - 357459
dc.contributor.authorpl
Ghesquieres, Hervé
dc.contributor.authorpl
Jurczak, Wojciech - 129923
dc.date.accessionpl
2022-02-01
dc.date.accessioned
2022-04-08T06:14:05Z
dc.date.available
2022-04-08T06:14:05Z
dc.date.issuedpl
2021
dc.description.numberpl
4
dc.description.physicalpl
455-463
dc.description.volumepl
21
dc.identifier.doipl
10.1080/14712598.2021.1884677
dc.identifier.eissnpl
1744-7682
dc.identifier.issnpl
1471-2598
dc.identifier.uri
https://ruj.uj.edu.pl/xmlui/handle/item/290042
dc.languagepl
eng
dc.language.containerpl
eng
dc.rights*
Dodaję tylko opis bibliograficzny
dc.rights.licence
Bez licencji otwartego dostępu
dc.rights.uri*
dc.subtypepl
Article
dc.titlepl
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
dc.title.journalpl
Expert Opinion on Biological Therapy
dc.typepl
JournalArticle
dspace.entity.type
Publication
Affiliations

* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.

Views
8
Views per month
Views per city
Ashburn
2
Wroclaw
2
Dublin
1
Krakow
1
Toronto
1

No access

No Thumbnail Available